Form 4: ImmunityBio Director Bruce Wendel Acquires Stock Options

ImmunityBio Director Bruce Wendel reported the acquisition of 146,020 stock options with an exercise price of $2.36, vesting through December 2028.

Summary

• Bruce Wendel, a Director of ImmunityBio, Inc. (IBRX), acquired 146,020 stock options.
• The transaction date for the option grant was December 12, 2025.
• The exercise price for these options is $2.36 per share.
• The options have an expiration date of December 12, 2035.
• The vesting schedule is staggered: 48,673 shares vest on December 12, 2026; 48,673 shares vest on December 12, 2027; and 48,674 shares vest on December 12, 2028, leading to full vesting by December 12, 2028.
• Vesting is contingent on Mr. Wendel's continued service as a Service Provider under the 2025 Equity Incentive Plan.
• All unvested shares will fully vest immediately prior to a Change in Control, provided Mr. Wendel remains a Service Provider.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed as a positive signal, as it aligns the director's financial interests with the long-term success and stock price appreciation of the company. It suggests continued commitment from key personnel.

Positives

• The acquisition of stock options by a director aligns their interests with those of shareholders, potentially signaling confidence in the company's future performance.
• The options have a long expiration date (December 12, 2035), providing ample time for the stock price to appreciate above the exercise price of $2.36.

Risks

• The value of the stock options is subject to the future market price of ImmunityBio, Inc. common stock; if the stock price does not rise above the $2.36 exercise price, the options may expire worthless.
• Vesting is conditional on Bruce Wendel's continued service as a Service Provider, meaning the options could be forfeited if his service terminates before vesting dates.
• The 'Change in Control' clause, while potentially accelerating vesting, also introduces a dependency on external corporate events.

Future Outlook

The vesting schedule extending to December 2028, and the option expiration date in December 2035, indicate a long-term incentive structure designed to retain the director and align his interests with the company's sustained growth and performance. The potential for accelerated vesting upon a Change in Control also points to strategic considerations regarding future corporate events.

Industry Context

Granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, as well as other sectors, to incentivize long-term commitment and performance. It aligns the interests of the board members with those of shareholders by making their compensation partially dependent on the company's stock price appreciation. This particular grant is part of the company's 2025 Equity Incentive Plan.

Comparison to Industry Standards

• The use of stock options with a multi-year vesting schedule is a standard compensation tool for directors and executives across various industries, including biotech.
• The inclusion of a 'Change in Control' clause for accelerated vesting is also a common feature in equity incentive plans, designed to protect executive interests during M&A activities.
• Without specific details on comparable director compensation packages from similar-sized biotech companies or industry benchmarks, a direct quantitative comparison of the option grant's size or exercise price is not feasible from this filing alone.

Corporate Governance

Related Party Transactions

• The acquisition of stock options by Bruce Wendel, a Director of ImmunityBio, Inc., constitutes a related party transaction as it involves a key management personnel and the company.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholders, potentially leading to decisions that enhance long-term stock value.
• Employees: While not directly impacting all employees, the existence of an Equity Incentive Plan suggests a broader framework for incentivizing key personnel.

Next Steps

• Bruce Wendel's continued service as a Service Provider to meet vesting conditions.
• Potential exercise of options by Bruce Wendel after vesting and before the expiration date, assuming the stock price is above the exercise price.

Key Dates

Keywords

ImmunityBio, IBRX, Bruce Wendel, Form 4, Stock Options, Insider Transaction, Director Compensation, Equity Incentive Plan, Vesting, Change in Control